Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immunotherapies - Bicycle Therapeutics/Genentech

Next Previous
Drug Profile

Research programme: immunotherapies - Bicycle Therapeutics/Genentech

Latest Information Update: 04 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bicycle Therapeutics; Genentech
  • Class Antineoplastics; Bicyclic peptide drug conjugates; Bicyclic peptides; Immunotherapies; Peptide drug conjugates; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Dec 2024 Genentech terminates collaboration activities for one of the initial programs, also halted research on the first Expansion Option program, and terminated the second Expansion Option program, while the remaining collaboration program continues, prior to December 2024
  • 12 Jul 2022 Genentech excerised second option to Bicycle Therapeutics to discover, develop and commercialise additional Bicycle®-based immuno-oncology therapies
  • 24 Feb 2022 Preclinical trials in Cancer in United Kingdom (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top